1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1657-p ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von SUNGHO BEA und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: Chronic opioid use is associated with high risk of overdose and developing substance use disorder. GLP-1RAs may influence reward-related neurobehavioral pathways, however, their real-world effects on opioid-related outcomes are unclear. We evaluated the association between GLP-1RA use and risk of opioid overdose among individuals with chronic opioid use.
Methods
Using US claims data, we identified adults with chronic opioid use, defined as ≥90 days of any opioid use in the 180 days before and on the cohort entry, which was defined as date of initiation of GLP-1RA or SGLT-2i. The primary outcome was opioid overdose, and secondary outcomes included alcohol abuse/dependence and substance use disorders. Incidence rates (IR) and hazard ratios (HR) were estimated using Cox proportional hazards models in 1:1 propensity score-matched cohorts.
Results
GLP-1RA initiation was associated with a lower risk of opioid overdose compared with SGLT-2i use (HR 0.70, 95% CI 0.51-0.99). Reduced risks were also observed for alcohol abuse/dependence (HR 0.77, 95% CI 0.64-0.93) and severe substance use disorder (HR 0.84, 95% CI 0.72-0.97). No association was observed for the negative control outcome of influenza vaccination.
Conclusion
In a high-risk population with chronic opioid use, GLP-1RA initiation was associated with decreased risk of opioid overdose compared with SGLT-2i, supporting a potential neurobehavioral effect beyond glycemic control or weight loss. Disclosure S. Bea: None. E. Patorno: Research Support; Current; Boehringer Ingelheim International GmbH, AstraZeneca, Bayer AG, National Institute of Diabetes and Digestive and Kidney Diseases, Patient-Centered Outcomes Research Institute. Other - Royalties; Current; UpToDate. S. Kattinakere Sreedhara: None. D. Wexler: Other - Data Monitoring Committee; Ended; Novo Nordisk. Other - Data Monitoring Committee; Current; Amgen Inc. S. Cromer: Other - Spouse is employee of Depuy Synthes; Current; Johnson & Johnson. J. Paik: None. K. Bykov: None. Funding American Diabetes Association (1-25-PDF-66), National Institute of Health (K01AG068365)
Zitieren
APA
BEA, S., PATORNO, E., SREEDHARA, S. K., WEXLER, D., CROMER, S., PAIK, J., & BYKOV, K. (2026). 1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1657-p
Vancouver
BEA S, PATORNO E, SREEDHARA SK, WEXLER D, CROMER S, PAIK J, et al. 1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1657-p
BibTeX
@article{BEA2026,
author = {BEA, SUNGHO and PATORNO, ELISABETTA and SREEDHARA, SUSHAMA KATTINAKERE and WEXLER, DEBORAH and CROMER, SARA and PAIK, JULIE and BYKOV, KATSIARYNA},
title = {1657-P: Concomitant Use of GLP-1RAs and Chronic Opioids and Risk of Opioid Overdose and Substance Use Disorders},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1657-p}
}
EUVIMED